Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations
暂无分享,去创建一个
M. Polley | Shaji K. Kumar | J. Fink | R. Ketterling | Cherisse A. Marcou | D. V. Van Dyke | K. Reichard | D. Viswanatha | P. Greipp | L. Baughn | Kathryn E. Pearce | L. Frederick | C. Williamson | R. Rowsey | Jess F. Peterson
[1] Shaji K. Kumar,et al. The multiple myelomas — current concepts in cytogenetic classification and therapy , 2018, Nature Reviews Clinical Oncology.
[2] G. Morgan,et al. Hyperhaploid karyotypes in multiple myeloma , 2017, Oncotarget.
[3] Pingping Qu,et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma , 2017, Haematologica.
[4] B. Barlogie,et al. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma , 2017, Leukemia.
[5] Shaji K. Kumar,et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. , 2017, Blood advances.
[6] R. Fonseca,et al. Trends in overall survival and costs of multiple myeloma, 2000–2014 , 2016, Leukemia.
[7] S Vincent Rajkumar,et al. Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management , 2016, American journal of hematology.
[8] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[9] D. Rossi,et al. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature , 2016, Oncotarget.
[10] M. Mohty,et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? , 2015, Blood.
[11] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Gordon Cook,et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Dimopoulos,et al. Staging and prognostication of multiple myeloma , 2014, Expert review of hematology.
[14] L. Campbell,et al. Hyperhaploid plasma cell myeloma. , 2012, Cancer genetics.
[15] B. Johansson,et al. Disease‐associated patterns of disomic chromosomes in hyperhaploid neoplasms , 2012, Genes, chromosomes & cancer.
[16] A. Al-Katib,et al. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes , 2007, American journal of hematology.
[17] N. Pandis,et al. Cytogenetic manifestations of multiple myeloma heterogeneity , 2005, Genes, chromosomes & cancer.
[18] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.
[19] R. Advani,et al. Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision of the World Health Organization classi fi cation of lymphoid neoplasms , 2016 .